The Combined Usage of Clinical Physical Finding in Management of COVID 19 Patients

July 30, 2024 updated by: Chia-hsi Chen, St. Martin De Porress Hospital

The Combined Usage of Clinical Physical Finding With Simple Triage and Rapid Treatment (START), Modified Early Warning Score(MEWS)and Quick Sequential Organ Failure Assessment(qSOFA) in Management of COVID 19 Patients

Physiological indicators such as blood pressure, heart rate, respiratory rate, and consciousness status of COVID-19 patients are used to apply the START (simple triage and rapid treatment, START), Modified Early Warning Score (MEWS), and quick Sequential Organ Failure Assessment (qSOFA) as tools for assessing clinical symptom tracking, deterioration, and subsequent improvement in COVID-19 patients. In response to the need for scarce manpower when a large number of emergency patients appear, a simple and easy-to-operate assessment method is adopted for mild patients, and artificial intelligence technology can be further used to assist in the assessment for early response and medication.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Due to the development of the pandemic , the virus has constantly mutated, leading to a vast majority of mild cases. This has significantly increased the burden on medical personnel. The investigators are trying to find a way to track whether their clinical symptoms have worsened. At the same time, the investigators want to know the changes in patient symptoms in real-time through online monitoring This is a single-center retrospective study of a group of COVID-19 patients. Review their medical records, mainly based on hospital field records and existing physiological indicators of patients such as blood pressure, heart rate, respiratory rate, and consciousness status. The partients visited the hospital between March 2020 and September 2022. All patients were given physiological value indicators MEWS, qSOFA, and START for scoring and assess the clinical symptom deterioration of COVID-19 patients.

In this study, The investigators collect the physiological values of each patient and the data on the nursing records during hospitalization to judge whether the symptoms have worsened

Study Type

Observational

Enrollment (Actual)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Tainan, Taiwan, 60069
        • St. Martin De Porres Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

COVID 19 patients were treated in the hospital between March 2020 and Sep.2022

Description

Inclusion Criteria:

  • a group of hospitalized COVID 19 patients were treated in the hospital between March 2020 and Sep.2022

Exclusion Criteria: Exclude patients who lack information in their medical records and incomplete clinical data.

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COVID 19 pandemic
Time Frame: March 2020 and September 2022
Assessing clinical symptom tracking, deterioration, and subsequent improvement in COVID-19 patients.
March 2020 and September 2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Martin De Porress Hospital

Investigators

  • Principal Investigator: Chia-Hsi Chen, MD, St. Martin De Porres Hospital,emergency medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2020

Primary Completion (Actual)

May 1, 2022

Study Completion (Actual)

July 20, 2024

Study Registration Dates

First Submitted

July 29, 2024

First Submitted That Met QC Criteria

July 29, 2024

First Posted (Actual)

July 30, 2024

Study Record Updates

Last Update Posted (Actual)

August 1, 2024

Last Update Submitted That Met QC Criteria

July 30, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 22B-005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Pandemic

Clinical Trials on COVID 19 pandemic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe